Endocrine Practice最新文献

英文中文

New-Onset Diabetes Before and After the Covid-19 Pandemic: A Comparative Clinical Analysis Covid-19大流行前后新发糖尿病的比较临床分析

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.147

Nancy Nakhoul MD, MSc, Tracy Nakhoul, Souheil Hallit PhD, Laurette Nakhoul MD

引用次数: 0

Comparison of Body Mass Index and Waist Circumference in the Prediction of Diabetes: A Retrospective Longitudinal Study 体重指数和腰围预测糖尿病的比较：一项回顾性纵向研究

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.170

Adel Gassab Mohammed MD, FACE, CABM(Endo.), MSc (Endocrinology), Dheyaa Kadhim AlWaeli MD, CABM(Endo.), MSc (Endocrinology)

引用次数: 0

Hyperthyroidism in Pregnancy: A Case Series in a Resource-Limited Set Up 妊娠期甲状腺机能亢进：资源有限地区的病例系列

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.189

Vishwa Unadkat MBBS, MD (Internal Medicine), Post Graduate Diploma in Clinical Endocrinology, Fellow in Diabetes

引用次数: 0

Impact of Ramadan Fasting on Thyroid Hormones, Medication Adherence, and Quality of Life in Hypothyroidism 斋月禁食对甲状腺功能减退患者甲状腺激素、药物依从性和生活质量的影响

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.191

Nazish Fatima MBBS, FCPS (MED), FCPS (ENDO), Faryal Tariq MBBS, MSc, Faiza Aslam MBBS, FCPS (MED), Sabiha Banu MBBS, FCPS (MED), FCPS (ENDO), Darshan Kumar MBBS, FCPS (MED), Musarrat Riaz MBBS, FCPS (MED), FCPS (ENDO)

引用次数: 0

Prevalence of Neuropathy and Its Associated Factors Among Patients With Diabetes Presenting to the Specialist Diabetes and Endocrine Center in Taif, Saudi Arabia: Cross-Sectional Study 沙特阿拉伯塔伊夫专科糖尿病和内分泌中心的糖尿病患者神经病变患病率及其相关因素：横断面研究

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.151

Saad Alfaez

引用次数: 0

Comparative Effect of Losartan and Atorvastatin on Streptozotocin-Induced Diabetic Retinopathy in Rats 氯沙坦与阿托伐他汀对链脲佐菌素所致大鼠糖尿病视网膜病变的比较作用

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.138

Amina Unis PhD Pharmacology, Suzan Darwish PhD Pharmacology, Samia Ali PhD Pharmacology, Gregory Liou PhD Ophthalmology, Hanane Tayel PhD Pathology

引用次数: 0

Immunologic Heterogeneity in Type 1 Diabetes Onset in an Indian Cohort 印度1型糖尿病发病的免疫学异质性

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.140

Md Alam MBBS, MD, DrNB, Endocrinology Resident, Mohammad Salem Baba MBBS, MD, DM, Mohammad Hayat Bhat MBBS, MD, DM, Basharat Quyoom Dar MBBS, MD, Shahnaz Mir MBBS, MD, DM, Abid Hussain Bhat MBBS, MD, DM, Madhumita Singh MBBS, MD, Ruchi Agrwal MBBS, MD, Uzair Ul Haq MBBS, MD, Muzafar Amin MBBS, MD

引用次数: 0

SDHB Mutation and Chronic Hypoxia: Dual Drivers of Paraganglioma in Cyanotic Congenital Heart Disease SDHB突变和慢性缺氧：紫绀型先天性心脏病副神经节瘤的双重驱动因素

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.09.160

Md Alam MBBS, MD, DrNB Resident, Mohammad Hayat Bhat MBBS, MD, DM, Shahnaz Mir MBBS, MD, DM, Abid Hussain Bhat MBBS, MD, DM, Mohammad Salem Baba MBBS, MD, DM, Basharat Quyoom Dar MBBS, MD

引用次数: 0

Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism palopegteriparatite治疗甲状旁腺功能低下患者的早期美国现实世界治疗模式和结果。

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.08.008

Timothy Graham MD , Dolores M. Shoback MD , Lisa Abbott MD , Sara Lubitz MD , Gary Edelson MD , Adnan Haider MD , Steven W. Ing MD , Micol S. Rothman MD , Natalie E. Cusano MD, MS , Carol Zhao MS , Jenny Ukena MD , Mark Schneider MD, MPH , Christopher T. Sibley MD , Mishaela R. Rubin MD

Objective

To examine the impact of palopegteriparatide (YORVIPATH; TransCon PTH) on real-world clinical outcomes in adult patients with hypoparathyroidism.

Methods

Adult patients with hypoparathyroidism who enrolled in the U.S. expanded access program as of October 2024 and provided consent were included in the analysis. Palopegteriparatide was administered at a recommended starting dose of 18 μg/day and titrated alongside conventional therapy (calcitriol and calcium). Conventional therapy requirements, palopegteriparatide dosing, serum calcium levels, and adverse events were assessed up to 12 months of treatment.

Results

Among 135 patients enrolled in the expanded access program who received at least 1 dose of palopegteriparatide, 123 provided consent for data use and were included in analysis. Nearly all patients (95.1%, 117/123) were previously treated with short-lived parathyroid hormone (PTH) therapy (primarily teriparatide or recombinant human PTH [1-84]), and 50.4% (62/123) switched directly from short-lived PTH or PTH-related protein therapy to palopegteriparatide. There was no clinically meaningful difference (>3 μg) in palopegteriparatide dose between direct switch and nondirect switch patients, with a similar trend over time. With palopegteriparatide treatment, the proportion of patients achieving independence from conventional therapy (defined as taking no calcitriol and ≤600 mg/day of elemental calcium) increased over 12 months. Mean serum calcium levels remained within the reference range (8.3-10.6 mg/dL) with palopegteriparatide, and no new safety signals were identified with up to 12 months of treatment.

Conclusion

This real-world analysis of palopegteriparatide treatment of hypoparathyroidism outside of a clinical trial setting reaffirms its efficacy and safety profile and provides insights into outcomes associated with different treatment transition practices.

目的：研究palopegteriparatide （YORVIPATH®；TransCon®PTH）对成年甲状旁腺功能减退症患者实际临床结果的影响。方法：于2024年10月加入美国扩大准入计划（EAP）并提供同意书的成年甲状旁腺功能减退患者纳入分析。Palopegteriparatide的推荐起始剂量为18 μg/d，并与常规治疗（骨化三醇和钙）一起滴定。常规治疗要求、palopegteriparatide剂量、血清钙水平和不良事件被评估至治疗12个月。结果：在纳入EAP的135名接受至少一剂palopegteriparatide的患者中，123名提供了数据使用同意书并被纳入分析。几乎所有患者（95.1%,117/123）之前都接受过短期PTH治疗（主要是特立帕肽或rhPTH(1-84)）， 50.4%（62/123）的患者直接从短期PTH或PTHrP治疗切换到palopegteriparide。直接切换组与非直接切换组间palopegteriparatide剂量差异无临床意义（>.3 μg），且随时间变化趋势相似。使用palopegteriparatide治疗，在12个月内从常规治疗（定义为不服用骨化三醇和≤600 mg/天的元素钙）中获得独立的患者比例增加。palopegteriparatide的平均血钙水平保持在参考范围（8.3-10.6 mg/dL），并且在长达12个月的治疗中没有发现新的安全性信号。结论：在临床试验之外对palopegteriparatide治疗甲状旁腺功能低下的实际分析重申了其有效性和安全性，并提供了与不同治疗过渡实践相关的结果的见解。

{"title":"Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism","authors":"Timothy Graham MD , Dolores M. Shoback MD , Lisa Abbott MD , Sara Lubitz MD , Gary Edelson MD , Adnan Haider MD , Steven W. Ing MD , Micol S. Rothman MD , Natalie E. Cusano MD, MS , Carol Zhao MS , Jenny Ukena MD , Mark Schneider MD, MPH , Christopher T. Sibley MD , Mishaela R. Rubin MD","doi":"10.1016/j.eprac.2025.08.008","DOIUrl":"10.1016/j.eprac.2025.08.008","url":null,"abstract":"<div><h3>Objective</h3><div>To examine the impact of palopegteriparatide (YORVIPATH; TransCon PTH) on real-world clinical outcomes in adult patients with hypoparathyroidism.</div></div><div><h3>Methods</h3><div>Adult patients with hypoparathyroidism who enrolled in the U.S. expanded access program as of October 2024 and provided consent were included in the analysis. Palopegteriparatide was administered at a recommended starting dose of 18 μg/day and titrated alongside conventional therapy (calcitriol and calcium). Conventional therapy requirements, palopegteriparatide dosing, serum calcium levels, and adverse events were assessed up to 12 months of treatment.</div></div><div><h3>Results</h3><div>Among 135 patients enrolled in the expanded access program who received at least 1 dose of palopegteriparatide, 123 provided consent for data use and were included in analysis. Nearly all patients (95.1%, 117/123) were previously treated with short-lived parathyroid hormone (PTH) therapy (primarily teriparatide or recombinant human PTH [1-84]), and 50.4% (62/123) switched directly from short-lived PTH or PTH-related protein therapy to palopegteriparatide. There was no clinically meaningful difference (>3 μg) in palopegteriparatide dose between direct switch and nondirect switch patients, with a similar trend over time. With palopegteriparatide treatment, the proportion of patients achieving independence from conventional therapy (defined as taking no calcitriol and ≤600 mg/day of elemental calcium) increased over 12 months. Mean serum calcium levels remained within the reference range (8.3-10.6 mg/dL) with palopegteriparatide, and no new safety signals were identified with up to 12 months of treatment.</div></div><div><h3>Conclusion</h3><div>This real-world analysis of palopegteriparatide treatment of hypoparathyroidism outside of a clinical trial setting reaffirms its efficacy and safety profile and provides insights into outcomes associated with different treatment transition practices.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 12","pages":"Pages 1568-1575"},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deep Learning for the Diagnosis and Treatment of Thyroid Cancer: A Review 深度学习在甲状腺癌诊断和治疗中的应用综述。

IF 4.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Endocrine Practice

Pub Date : 2025-12-01 DOI: 10.1016/j.eprac.2025.07.020

Rili Gao MD, PhD , Shangqing Mai BBA , Song Wang BE , Wuqiang Hu BM , Zhangqi Chang LLB , Guozhi Wu BM , Haixia Guan MD, PhD

Objective

In recent years, the application of deep learning (DL) technology in the thyroid field has expanded rapidly, driving substantial innovation in thyroid disease research. This review aims to provide clinicians with the latest research advances in the application of DL to the diagnosis and treatment of thyroid cancer.

Methods

A systematic review was conducted of studies published in the past five years in the PubMed database on the application of deep learning in the diagnosis, treatment, and prognosis of thyroid cancer.

Results

DL has made substantial advances in the diagnosis and treatment of thyroid cancer, particularly through the application of advanced models such as convolutional neural networks, long short-term memory networks, and generative adversarial networks. These models have delivered breakthrough performance in key areas, including ultrasound image analysis of thyroid nodules, automated classification of pathological images, and assessment of extrathyroidal extension. DL also shows considerable promise for individualized treatment planning and prognosis prediction. Nonetheless, its widespread clinical adoption is hindered by substantial technical, clinical, and ethical challenges. Addressing these barriers is crucial to achieving meaningful improvements in thyroid cancer care and realizing the full potential of DL in precision medicine.

Conclusion

DL techniques are advancing the precision diagnosis and treatment of thyroid cancer and hold the potential to enhance diagnostic accuracy and improve therapeutic outcomes for patients.

近年来，深度学习（DL）技术在甲状腺领域的应用呈指数级增长，极大地推动了甲状腺疾病研究的创新。作为内分泌系统最常见的恶性肿瘤，甲状腺癌的准确诊断和治疗一直是临床研究的重点。本文系统综述了深度学习在甲状腺恶性肿瘤诊断和治疗中的最新研究进展，重点介绍了卷积神经网络（cnn）、长短期记忆网络（LSTMs）和生成对抗网络（gan）等先进模型在甲状腺结节超声图像分析、病理图像自动分类、甲状腺外展评估等关键领域的突破性应用。此外，该综述强调了深度DL技术在个体化治疗计划和预后预测方面的巨大潜力。分析了目前DL在甲状腺癌诊疗中的应用所面临的技术瓶颈和临床挑战，展望了未来的发展方向。本文旨在为临床医生提供最新的研究见解，促进甲状腺癌精准诊疗体系的进一步完善，最终实现甲状腺癌患者更好的诊断和治疗效果。

{"title":"Deep Learning for the Diagnosis and Treatment of Thyroid Cancer: A Review","authors":"Rili Gao MD, PhD , Shangqing Mai BBA , Song Wang BE , Wuqiang Hu BM , Zhangqi Chang LLB , Guozhi Wu BM , Haixia Guan MD, PhD","doi":"10.1016/j.eprac.2025.07.020","DOIUrl":"10.1016/j.eprac.2025.07.020","url":null,"abstract":"<div><h3>Objective</h3><div>In recent years, the application of deep learning (DL) technology in the thyroid field has expanded rapidly, driving substantial innovation in thyroid disease research. This review aims to provide clinicians with the latest research advances in the application of DL to the diagnosis and treatment of thyroid cancer.</div></div><div><h3>Methods</h3><div>A systematic review was conducted of studies published in the past five years in the PubMed database on the application of deep learning in the diagnosis, treatment, and prognosis of thyroid cancer.</div></div><div><h3>Results</h3><div>DL has made substantial advances in the diagnosis and treatment of thyroid cancer, particularly through the application of advanced models such as convolutional neural networks, long short-term memory networks, and generative adversarial networks. These models have delivered breakthrough performance in key areas, including ultrasound image analysis of thyroid nodules, automated classification of pathological images, and assessment of extrathyroidal extension. DL also shows considerable promise for individualized treatment planning and prognosis prediction. Nonetheless, its widespread clinical adoption is hindered by substantial technical, clinical, and ethical challenges. Addressing these barriers is crucial to achieving meaningful improvements in thyroid cancer care and realizing the full potential of DL in precision medicine.</div></div><div><h3>Conclusion</h3><div>DL techniques are advancing the precision diagnosis and treatment of thyroid cancer and hold the potential to enhance diagnostic accuracy and improve therapeutic outcomes for patients.</div></div>","PeriodicalId":11682,"journal":{"name":"Endocrine Practice","volume":"31 12","pages":"Pages 1608-1614"},"PeriodicalIF":4.6,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Endocrine Practice

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀